EMEA-003569-PIP01-23 - paediatric investigation plan

Raludotatug deruxtecan
PIPHuman

Key facts

Active Substance
Raludotatug deruxtecan
Therapeutic area
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Decision number
P/0100/2024
PIP number
EMEA-003569-PIP01-23
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of fallopian tube cancer
  • Treatment of ovarian cancer
  • Treatment of primary peritoneal cancer
Route(s) of administration
Intravenous use
Contact for public enquiries

Daiichi Sankyo Europe GmbH

E-mail: service@daiichi-sankyo.eu
Tel.: +49 8978080

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page